Investor Relations

The Ambu share has a track record of high performance. And growth is a strong parameter for our success

Latest news


Feb. 2019

Ambu Extends Major US Contracts

Three nation-wide contracts that run from 2019 to 2022-2023 and ensure delivery of livesaving devices to hospitals and emergency services.

Ambu is pleased to announce an agreement with HealthTrust Purchasing Group (HPG) to extend the National Dual Award Resuscitation and Hyperinflation Agreement for a five-year term. Under a five-year contract that began January 1, 2019, Ambu is one of two contracted suppliers for HPG members for the category of Resuscitation and Hyperinflation Bags. For the first time, HPG Members also have the option of a deeper partnership with Ambu via a committed tier that is available for this five-year term.

The dual award of the HPG Resuscitation and Hyperinflation contract reinforces Ambu’s position as the market leader in this category. "At Ambu, we are immensely proud to be a preferred supplier of lifesaving devices. The Ambu bag resuscitator was a revolution in first aid when we invented it in 1956, and – through subtle innovations and improvements during the years – it continues to be a crucial piece of equipment in modern health care," says Lars Marcher, CEO of Ambu.

In addition, Ambu announces an agreement with HPG to extend the Sole Award Agreement for a four-year term. Under a four-year contract that began February 1, 2019, Ambu is the sole supplier for HPG members for the category of Anesthesia Breathing Circuits and Face masks. "It’s absolutely crucial for doctors, nurses and paramedics to have easy access to high quality devices. We're proud that HPG has seen fit to extend our exclusive contract on anesthesia products for four more years making it possible for us to contribute to saving lives and improving patient care," says Lars Marcher.

The Original Ambu Resuscitator
Since 1956 when they introduced the first manual resuscitator to the market, Ambu has been the global leader in providing resuscitation solutions to healthcare providers. Featuring the SPUR II disposable resuscitator, Ambu offers a comprehensive portfolio of products which also includes reusable resuscitators, hyperinflation systems, a number of innovative anesthesia circuits and face masks. With a focus not only on patient care but also ease of use, the “Ambu bag” has been the resuscitator of choice for generations of clinicians, helping to save patients’ lives for over six decades and counting.

Read more online
Learn more about Ambu’s anesthesia solutions.

You can download this press release (pdf).


Feb. 2019

Capital increase in connection with exercise of warrants (no. 7)

In December 2013, Ambu A/S issued 2,000,000 warrants and in December 2015 770,000 warrants, each warrant entitling the holder to subscribe for one Class B share with a nominal value of DKK 0.50. 52 individuals participate in the 2013 scheme and 46 individuals participate in the 2015 scheme. In both cases, the vesting period is three years, and both schemes can therefore be exercised in the trading window that opened on 31 January 2019 in connection with Ambu’s interim financial report for Q1 2018/19.

Since 31 January 2019, instructions have been received to exercise warrants as follows:

  • 2013 scheme: One individual has issued instructions to exercise a total of 50,000 warrants at the agreed exercise price of DKK 13.26 per share with a nominal value of DKK 0.50.
  • 2015 scheme: Five individuals have issued instructions to exercise a total of 80,000 warrants at the agreed exercise price of DKK 39.26 per share with a nominal value of DKK 0.50.

Today Ambu’s Board of Directors decided to carry out the capital increase relating to the exercised warrants.

As a result of the capital increase, the share capital of Ambu will be increased by a nominal amount of DKK 65,000 from DKK 125,689,800 to DKK 125,754,800 through the issue of 130,000 Class B shares.

Following this and in consideration of the employees having left the company, there are 100,000 remaining warrants under the 2013 scheme being held by four individuals and 570,000 remaining warrants under the 2015 scheme being held by 34 individuals. 

The new B shares are expected to be admitted to trading and official listing on NASDAQ Copenhagen A/S on 14 February 2019 under the ISIN code of Ambu A/S’ existing B shares (DK0060946788).

Under section 10 of the Danish Executive Order on disclosure requirements for issuers, Ambu A/S is to announce the total share capital and the total voting rights by the end of a month in which any change of the share capital was effected. The table below shows the total share capital and the total voting rights of Ambu A/S after the capital increase.


Number of shares (nominal value DKK 0.50)

Nominal value (DKK)

Voting rights

A shares




B shares









Download this announcement as pdf Company Announcement 7 2018-19


Feb. 2019

Allan Søgaard Larsen withdraws from Ambu’s Board of Directors (no. 6)

Allan Søgaard Larsen, who since 2011 has been a member of the Board in Ambu A/S, has for personal reasons decided to withdraw from the Board with immediate effect.

The entire Board would like to thank Allan for his considerable contribution to Ambu’s successful development.

You can download this company announcement (pdf).

Annual General Meeting 2018
(Generalforsamling 2018)

The AGM was held on 12 December in Copenhagen. See full video transmission

Go to Annual General Meeting

Financial Reports

Get the latest annual & quarterly reports
Read more

Annual Key Figures

Get an overview of Ambu's key figures
Read more


Get the latest investor presentations and webcasts
Read more


Learn more about Ambu's present strategy
Read more

Upcoming events


Mar. 2019

ABG Q1 roadshow

New York and Salt Lake City
4-5 March 2019


Mar. 2019

Carnegie Nordic Healthcare Seminar

5-6 March 2019


Mar. 2019

Nordea reversed roadshow

13-14 March 2019

News from Ambu

Sign up and receive news and company announcements from Ambu

Sign up